Calmodulin kinase II regulates amphetamineinduced reverse transport in the dopamine transporter: implications for the importance of the dopamine transporter in Angelman syndrome 
Results
Both pharmacological inhibition of CamKIIa or genetic ablation of CaMKIIa function (in CaMKIIa knock-out and AS mice) reduces amphetamine-induced reverse transport in the DAT. As CaMKIIa is one of the brain's most abundant proteins involved in a plethora of regulatory processes it is not possible to pharmacologically target it in human AS patients. However, the DAT would be a possible target also for these patients and it might be promising to further investigate potential DAT influencing medications to treat Angelman syndrome.
Conclusions
Pharmacologic inhibition of CamKIIa as well as genetic knock-out or activity-downregulation of CamKIIa reduce amphetamine-induced reverse transport in the DAT.
